Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glyoxylate (also known as glyoxylic acid) is an endogenous two-carbon alpha-keto-acid and metabolic intermediate. It is being developed as a novel, fast-acting therapeutic antidote for cyanide poisoning. Unlike traditional cyanide countermeasures that rely solely on chemical scavenging or chelation, glyoxylate acts through a dual mechanism: it directly reacts with cyanide to form a stable cyanohydrin adduct, and it undergoes metabolism by lactate dehydrogenase (LDH) to reverse cyanide-induced redox imbalances in both the cytosol and mitochondria. Additionally, preclinical research has explored glyoxylate as a potential therapeutic or preventive agent in colorectal cancer, where its administration leads to glycine accumulation via alanine-glyoxylate aminotransferase (AGXT) activity, triggering glycine receptor-mediated calcium dysregulation and apoptosis in tumor cells. In laboratory research, glyoxylate is also widely utilized as a reagent to induce calcium oxalate nephrolithiasis (kidney stones) in animal models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glyoxylate.